Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results
Company to Host Webcast on 12th July at 9am AEST (7pm ET, 11 July)
Author Archives: admin
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 325,000 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 55,000 shares of Arcutis’ common stock to 43 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
Read the rest here:
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BC Platforms Announces Appointment of New Chairman, Alex Dickinson
Serial entrepreneur and precision medicine technologist to drive strategic agenda at BC Platforms Serial entrepreneur and precision medicine technologist to drive strategic agenda at BC Platforms
See original here:
BC Platforms Announces Appointment of New Chairman, Alex Dickinson
Spectral AI Expands Clinical Trial Sites for Pivotal U.S. Burn Study
DALLAS, July 03, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has added two new U.S. Clinical Trial Sites for its 2024 Burn Pivotal Study: the University of California San Diego and the University of Utah.
See the rest here:
Spectral AI Expands Clinical Trial Sites for Pivotal U.S. Burn Study
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders.
See original here:
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., July 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provided an update on the Phase 1b/2 “DURIPANC” study of Ampligen and AstraZeneca’s Imfinzi as a combination therapy for late-stage pancreatic cancer. The Company also provided a business update, including that as a result of recent financings, AIM recently had stockholders’ equity of $6.9 million.
Visit link:
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society…
Multiple studies confirm ART12.11’s superior advantages as a product candidate for the treatment of anxiety related disorders Multiple studies confirm ART12.11’s superior advantages as a product candidate for the treatment of anxiety related disorders
Follow this link:
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society...
Rafarma pharmaceutical updates: creation of a joint research and production enterprise in Busan (South Korea) between Rafarma and the Korean…
Sheridan, Wyoming, USA, July 03, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - Rafarma Pharmaceuticals is pleased to announce the signing of a preliminary agreement to establish a joint industrial venture in Busan Technology Park (South Korea) as the Dongnam Industrial Park of Radiological & Medical Sciences. The partners in the venture are Rafarma and the Korean pharmaceutical company Woods Medical Care.
Read this article:
Rafarma pharmaceutical updates: creation of a joint research and production enterprise in Busan (South Korea) between Rafarma and the Korean...
IVI RMA Global and Lavima Fertility join forces in research in fertility treatments
VALENCIA, Spain and BRUSSELS, July 03, 2024 (GLOBE NEWSWIRE) -- Seeking alternatives to obtain oocytes without ovarian stimulation is a pioneering line of research in reproductive medicine. The inconveniences that the process of ovarian stimulation can generate are a current barrier for some women and couples who are considering starting a reproductive treatment. In fact, 1 out of every 5 couples do not start the search for a second child for this reason.
See the original post here:
IVI RMA Global and Lavima Fertility join forces in research in fertility treatments
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
Go here to see the original:
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371